We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+0.6%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$4.46M
Cap. Flow
-$3.52M
Cap. Flow %
-3.14%
Top 10 Hldgs %
40.26%
Holding
80
New
27
Increased
7
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$4.23M
2
CABA icon
Cabaletta Bio
CABA
+$3.68M
3
AUTL
Autolus Therapeutics
AUTL
+$3.62M
4
AMGN icon
Amgen
AMGN
+$3.47M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$3.41M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$4.64M
2
RDY icon
Dr. Reddy's Laboratories
RDY
+$3.56M
3
RNAM
Avidity Biosciences
RNAM
+$3.45M
4
CLDX icon
Celldex Therapeutics
CLDX
+$2.98M
5
GERN icon
Geron
GERN
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
26
Natera
NTRA
$36.1B
$2.02M 1.8%
18,650
– –
BHVN icon
27
Biohaven
BHVN
$2.07B
$2.01M 1.79%
+57,800
New +$2.29M
BBIO icon
28
BridgeBio Pharma
BBIO
$16.8B
$2M 1.78%
78,907
+30,100
+62% +$823K
FULC icon
29
Fulcrum Therapeutics
FULC
$248M
$1.88M 1.67%
+302,700
New +$2.29M
APLS
30
DELISTED
Apellis Pharmaceuticals
APLS
$1.8M 1.6%
+46,900
New +$2.12M
ATEC icon
31
Alphatec Holdings
ATEC
$1.43B
$1.69M 1.51%
+162,100
New +$1.89M
ABCL icon
32
AbCellera Biologics
ABCL
$1.62B
$1.52M 1.36%
+514,900
New +$1.95M
ZLAB icon
33
Zai Lab
ZLAB
$2.1B
$1.5M 1.34%
86,700
+21,400
+33% +$376K
PLRX icon
34
Pliant Therapeutics
PLRX
$66.3M
$1.33M 1.19%
+124,000
New +$1.6M
RZLT icon
35
Rezolute
RZLT
$474M
$1.21M 1.08%
+282,400
New +$970K
ALVO icon
36
Alvotech
ALVO
$1.05B
$1.2M 1.07%
+99,000
New +$1.32M
GOSS icon
37
Gossamer Bio
GOSS
$100M
$1.02M 0.9%
+1,127,699
New +$844K
ELEV
38
DELISTED
Elevation Oncology
ELEV
$997K 0.89%
369,322
– –
ESTA icon
39
Establishment Labs
ESTA
$2.7B
$986K 0.88%
+21,700
New +$1.1M
SYRS
40
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$821K 0.73%
+159,175
New +$836K
QTRX icon
41
Quanterix
QTRX
$164M
$788K 0.7%
59,650
– –
QTTB icon
42
Q32 Bio
QTTB
$467M
$787K 0.7%
43,865
-21,156
-33% -$506K
VYNE icon
43
VYNE Therapeutics
VYNE
$19.1M
$696K 0.62%
7,069
-1,240
-15% -$155K
PMVP icon
44
PMV Pharmaceuticals
PMVP
$58.7M
$581K 0.52%
+358,400
New +$646K
APRE icon
45
Aprea Therapeutics
APRE
$7.6M
$558K 0.5%
+137,174
New +$707K
TECX
46
Tectonic Therapeutic
TECX
$562M
$533K 0.47%
32,389
+27,294
+536% +$437K
ADAG
47
Adagene
ADAG
$246M
$462K 0.41%
150,876
-4,507
-3% -$12.1K
NBP
48
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$453K 0.4%
271,400
-54,362
-17% -$97.1K
PROC
49
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
$321K 0.29%
+126,901
New +$343K
HLVX
50
DELISTED
HilleVax
HLVX
$260K 0.23%
+18,000
New +$247K
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
GIO
Galilei Investment Office London, United Kingdom $193M AUM 16.19% 1-Year Est. Return

Exome Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Exome Asset Management held 80 positions worth $112M, down 3.8% from $117M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management withdrew a net $3.52M in Q2 2024, closing 28 positions and reducing 10 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $4.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Sarepta Therapeutics worth $5.2M.

  • Exome Asset Management's largest Q2 2024 buy was Sarepta Therapeutics: 32,900 shares worth $5.2M.
  • Exome Asset Management added most to BridgeBio Pharma in Q2 2024, an estimated $823K increase.
  • Exome Asset Management's biggest Q2 2024 reduction was Dr. Reddy's Laboratories, cutting an estimated $3.56M.
  • Exome Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $4.64M.
  • Exome Asset Management's ten largest holdings make up 40% of its $112M portfolio in Q2 2024.
  • Exome Asset Management opened 27 new positions and closed 28 in Q2 2024.
  • Exome Asset Management's portfolio value fell 3.8% quarter-over-quarter to $112M.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.